A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
Active, not recruiting · Phase 3 · NCT06764485
Conditions: Metastatic Castration-resistant Prostate Cancer
At a glance
- Research payments reported, 2025
- $17,510
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 960
About the trial
- Sponsor
- Celgene
- Tested
- BMS-986365 (drug), Enzalutamide (drug), Abiraterone (drug), Docetaxel (drug), Predinsone/Prednisolone (drug)
- Dates
- Started 2025-03-13; completion 2029-01-19
- Results posted
- Not yet
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
From ClinicalTrials.gov, last updated 2026-09-30. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $17,510 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $17,510
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.